Obesity rates in America by year: what the data shows
Decision brief
Answer first · skim in under a minute
This analysis summarizes obesity rates in America by year using the strongest available public-health data and explains why the trend matters for pharma BD and investors. It also places U.S. prevalence in the context of global obesity statistics and the standard BMI definition.
Obesity rates in America by year, measured by CDC NHANES, show adult obesity near 40% in the latest cycle: 40.3% age-adjusted prevalence during August 2021–August 2023. Severe obesity rose to 9.7%, while overall obesity did not change significantly across the prior decade of survey cycles.
Contents11 sections
Key Takeaways
- August 2021–August 2023 NHANES: age-adjusted adult obesity 40.3%; severe obesity 9.7%; overweight 31.7% (CDC Health E-Stat 111).
- 2017–March 2020 NHANES: age-adjusted adult obesity was 41.9% (NCHS reports).
- 2013–2014 to 2021–2023: overall obesity trend not significant; severe obesity increased from 7.7% to 9.7% (Data Brief 508).
- Obesity prevalence was higher at ages 40–59 than at 20–39 or 60+, and lower among adults with a bachelor’s degree or more.
What do the newest obesity rates in America by year show?
CDC’s Health E-Stat 111 reports that in August 2021–August 2023, the age-adjusted prevalence of obesity among U.S. adults age 20 and older was 40.3%, including 9.7% with severe obesity, with another 31.7% overweight (Health E-Stat 111).
NCHS Data Brief 508 presents the same cycle’s obesity estimate of 40.3% and notes no significant sex difference overall, with higher prevalence at ages 40–59 (Data Brief 508).
How have obesity rates changed across recent NHANES years?
Across four cycles used for 10-year trend testing—2013–2014, 2015–2016, 2017–March 2020, and August 2021–August 2023—age-adjusted obesity moved from 37.7% to 39.6% to 41.9% to 40.3%. CDC reports the overall obesity change over that span was not statistically significant.
- Severe obesity: 7.7% (2013–2014) → 9.7% (2021–2023)
- 2017–March 2020 obesity: 41.9% age-adjusted among adults 20+ (NHSR 158 PDF)
- PMC republication: PMC11744423
What subgroup patterns appear in the latest cycle?
Obesity prevalence was higher in adults ages 40–59 than in ages 20–39 and 60 and older. Adults with a bachelor’s degree or higher had lower obesity prevalence than adults with less education. Severe obesity was higher in women than men within each age group in Data Brief 508’s summary.
These gradients matter when sizing anti-obesity and cardiometabolic franchises by age and education proxies for coverage.
How should analysts use year-by-year obesity rates?
NHANES cycles are multi-year windows, not calendar-year point estimates. Comparing “2022 vs 2023” as if they were annual vitals can misstate precision. Prefer cycle labels (for example August 2021–August 2023) when citing rates.
Measured height and weight define BMI ≥30 as obesity and BMI ≥40 as severe obesity in these CDC publications.
What remains unproven?
National prevalence does not attribute recent flat overall obesity to any specific medicine class. Causal claims linking GLP-1 uptake to NHANES obesity trends require dedicated analyses beyond these descriptive briefs.
How do measured obesity rates differ from self-report surveys?
NHANES obesity prevalence uses measured height and weight collected in mobile examination centers, which reduces bias relative to telephone self-report. That is why CDC series remain the reference for U.S. adult obesity rates in America by year for epidemiologic monitoring.
Policy briefs and commercial forecasts that mix BRFSS self-report with NHANES measured rates without adjustment can invent false year-to-year swings. Stick to one measurement system when building time series for BD models.
Severe obesity (BMI ≥40) rising to 9.7% while overall obesity stays near 40% implies a shifting composition of the obese population toward higher BMI strata—the segment most often eligible for intensive anti-obesity pharmacotherapy and bariatric pathways.
What commercial scenarios follow from flat overall obesity?
If overall adult obesity holds near 40% while severe obesity climbs toward 10%, volume growth for anti-obesity medicines may come more from deeper penetration and longer persistence inside the severe and high-BMI obese cohorts than from a rising share of all adults crossing BMI 30.
Payers increasingly ask for cardiovascular and metabolic outcome evidence beyond kilograms lost. NHANES comorbidity companions—diabetes and hypertension prevalence in related NCHS reports—help size combination-risk populations that matter for outcomes-based contracts.
Investors should also watch pediatric obesity series separately; adult NHANES 20+ rates in Health E-Stat 111 are not interchangeable with ages 2–19 estimates published in other CDC briefs.
Related NovaPharma coverage
Frequently Asked Questions
What is the latest U.S. adult obesity rate by year?
During August 2021–August 2023, age-adjusted obesity prevalence among U.S. adults age 20 and older was 40.3%, according to CDC NHANES Health E-Stat 111 and NCHS Data Brief 508.
Has overall obesity prevalence kept rising every NHANES cycle?
From 2013–2014 through August 2021–August 2023, age-adjusted obesity did not change significantly, while severe obesity rose from 7.7% to 9.7%.
Why do year-by-year obesity rates matter for pharma?
Stable overall obesity near 40% with rising severe obesity shapes demand for anti-obesity medicines, comorbidity management, and long-term cardiovascular risk programs.
Primary Sources
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- Ensuring Compatibility for GLP-1-based Drugs — The rise of GLP-1 agonists like Semaglutide demands innovative ready-to-use cartridges to enhance de…